TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18593770
Drug: Octreotide-long-acting release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide-long-acting release (LAR) therapy
Study: 18596272
Drug: Motesanib diphosphate
Normalized name: trisodium diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib diphosphate (125 mg, orally once daily)
Study: 18598190
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine
Study: 18598891
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HT)
Study: 18606979
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (original DCCT treatment group assignment)
Study: 18606979
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment group
Study: 18612102
Drug: dmCODOX-M (methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: dmCODOX-M (methotrexate, dose 3 g/m(2)) with or without IVAC
Study: 18615172
Drug: Escitalopram (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10-20 mg/day) for 8 weeks
Study: 18617067
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of beta-blockers (1,350 patients, 56.9%)
Study: 18617067
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of beta-blockers (79 patients, 3.3%)
Study: 18617067
Drug: No beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blocker therapy (303 patients, 12.8%)
Study: 18617067
Drug: Newly started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Newly started beta-blockers (632 patients, 26.6%)
Study: 18619874
Drug: Lacosamide treatment
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide treatment during the study.
Study: 18619874
Drug: Lacosamide treatment
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide treatment at study termination.
Study: 18620563
Drug: Specialized addiction
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized addiction treatment plus treatment as usual
Study: 18621618
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy plus lapatinib
Study: 18621618
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy plus trastuzumab
Study: 18621618
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy plus both lapatinib and trastuzumab
Study: 18625666
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for > or = 4 h/night
Study: 18625666
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for < 4 h/night
Study: 18625762
Drug: High-dose lopinavir-ritonavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lopinavir-ritonavir (LPV/r) 400/100 mg/m(2) p.o. q12h without NNRTI
Study: 18625762
Drug: High-dose lopinavir-ritonavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lopinavir-ritonavir (LPV/r) 480/120 mg/m(2) p.o. q12h with NNRTI
Study: 18625762
Drug: Saquinavir (SQV)
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saquinavir (SQV) 750 mg/m(2) p.o. q12h added when LPV IQ <15
Study: 18625762
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment regimen (LPV/r with or without SQV)
Study: 18626272
Drug: Aripiprazole (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (20, 25, or 30 mg/d)
Study: 18626272
Drug: Aripiprazole (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (maximum dose for cohort for 14 days)
Study: 18635429
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin and rituximab
Study: 18639220
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide implant insertion combined with phacoemulsification and intraocular lens implantation
Study: 18643743
Drug: N-acetylcysteine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine and tigecycline catheter-lock solution for 14 days plus systemic antibiotic therapy
Study: 18650621
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (interferon- and gemcitabine-based)
Study: 18662932
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week for up to 20 weeks
Study: 18668591
Drug: Rilonacept (IL-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept (IL-1 Trap) 300 mg loading dose, followed by maintenance doses of 100 mg/week, with possible escalation to 160 mg/week and 320 mg/week.
Study: 18668591
Drug: Rilonacept (IL-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept (IL-1 Trap) 100 mg/week and higher doses (160 mg and 320 mg).
Study: 18668591
Drug: Rilonacept (IL-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept (IL-1 Trap) at higher doses (160 mg and 320 mg).
Study: 18668653
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg by mouth every 8 hours for 6 weeks (initial 2-week titration).
Study: 18668653
Drug: Pentoxifylline treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline treatment.
Study: 18669874
Drug: Thalidomide (THAL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (THAL, 200 mg/d) with monthly pamidronate
Study: 18669874
Drug: Low beta-2-microglobulin
Normalized name: Dianeal Low Calcium 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low beta-2-microglobulin levels less than 2 mg/L
Study: 18669874
Drug: Postsalvage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postsalvage therapy
Study: 18671877
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (10 g of gel containing 100 mg of testosterone)
Study: 18673542
Drug: Non-invasive cardiac
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive cardiac imaging algorithm followed by evidence-based treatment (including CT calcium scoring, CT angiography, and DSMR testing)
Study: 18681756
Drug: Citalopram, starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram, starting at 20 mg/day, increased to 40 mg/day by weeks 2-4, and to 60 mg/day by weeks 4-6.
Study: 18681756
Drug: Citalopram treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment.
Study: 18682513
Drug: Cabergoline (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (1.3 +/- 1.3 mg/wk, treatment duration 12-60 months in 32%, >60 months in 68%)
Study: 18682513
Drug: Cabergoline (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (cumulative dose above median)
Study: 18682513
Drug: Cabergoline (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (cumulative dose below median)
Study: 18682973
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
Study: 23226015
Drug: Treatment delay
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment delay
Study: 18694333
Drug: Fixed-dose pyronaridine-artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-dose pyronaridine-artesunate combination (6:2, 9:3, 12:4 mg/kg tablet coformulations and 9:3 mg/kg granule coformulation) administered once daily for 3 days
Study: 18694333
Drug: Fixed-dose pyronaridine-artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-dose pyronaridine-artesunate combination
Study: 18694338
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular dose of 90 microg of inactivated subvirion A/Vietnam/1203/2004 vaccine
Study: 18694338
Drug: Two 90-microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 90-microg doses in H5-naive subjects
Study: 18698002
Drug: Allogeneic donor
Normalized name: Allogeneic donor CD362 enriched human umbilical cord-derived mesenchymal stromal cells
DrugBank: Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells (DB15731)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic donor peripheral blood cells infusion after fludarabine and 200 cGy total body irradiation, with posttransplantation cyclosporine and mycophenolate mofetil.
Study: 18698002
Drug: Uninterrupted administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uninterrupted administration of highly active antiretroviral therapy (HAART).
Study: 18703791
Drug: Inter-alpha-trypsin inhibitor
Normalized name: Inter-alpha-trypsin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inter-alpha-trypsin inhibitor (IaI)
Study: 18703791
Drug: Inter-alpha-trypsin inhibitor
Normalized name: Inter-alpha-trypsin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inter-alpha-trypsin inhibitor (IaI) deficiency
Study: 18707849
Drug: Clarithromycin (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (1g within 1h of infusion for three consecutive days)
Study: 18713945
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg for 2 weeks, then 400 mg for 50 weeks) and rituximab (375 mg/m2 per week)
Study: 18722008
Drug: PTC124 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC124 at 16 mg/kg per day for 14 days (first cycle)
Study: 18722008
Drug: PTC124 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC124 at 40 mg/kg per day for 14 days (second cycle)
Study: 18726828
Drug: Leptin replacement
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin replacement treatment with recombinant methionyl human leptin for 24 months
Study: 18728159
Drug: Outpatient 1-yr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient 1-yr intervention program based on exercise, behavior, and nutrition therapy
Study: 18729192
Drug: PX-478 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PX-478 (20 mumol/L)
Study: 18729192
Drug: PX-478 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PX-478 (50 mumol/L)
Study: 18753661
Drug: 4-mm needle
Normalized name: NEEDLE,PEN 31G,4MM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mm needle for intramuscular injections
Study: 18757456
Drug: Serum CC-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CC-16 levels in individuals with COPD (n=1888)
Study: 18757456
Drug: Serum CC-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CC-16 levels in current smokers with COPD
Study: 18757456
Drug: Serum CC-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CC-16 levels in former smokers with COPD
Study: 18757456
Drug: Serum CC-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CC-16 levels in individuals without airflow obstruction (n=296)
Study: 18757456
Drug: Serum CC-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CC-16 levels in non-smokers (n=201)
Study: 18757456
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of serum CC-16 levels with age and gender in COPD subjects
Study: 18757456
Drug: Serum CC-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CC-16 levels in individuals with GOLD stage II and III COPD
Study: 18757456
Drug: Serum CC-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CC-16 levels in former smokers with reversible airflow obstruction
Study: 18761748
Drug: Rituximab treatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab treatment in aggregate-containing tissues
Study: 18761748
Drug: Rituximab treatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab treatment in aggregate-containing synovia
Study: 18769731
Drug: Recombinant methionyl
Normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant methionyl human leptin (r-metHuLeptin) at physiologic replacement doses of 0.03 mg/kg/day
Study: 18771667
Drug: 10 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg/day Silibinin (IV) for 7 days
Study: 18771667
Drug: 5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg/day Silibinin (IV) for 14 days
Study: 18771667
Drug: 10 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg/day Silibinin (IV) for 14 days
Study: 18771667
Drug: 15 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg/day Silibinin (IV) for 14 days
Study: 18771667
Drug: 20 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg/day Silibinin (IV) for 14 days
Study: 18776118
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II blockers added to ACE inhibitors
Study: 18776118
Drug: Dual RAAS
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual RAAS blockade (ACE inhibitors + Angiotensin II blockers)
Study: 18776118
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors alone
Study: 18779469
Drug: Dalteparin sodium,
Normalized name: dalteparin sodium,porcine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin sodium, 5000 IU once daily
Study: 18781879
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of L-AmB alone (group A)
Study: 18781879
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B)
Study: 18781879
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of L-AmB followed by miltefosine for 14 days (group C)
Study: 18781879
Drug: 3.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D)
Study: 18781879
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E)
Study: 18784101
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus cetuximab (cisplatin or carboplatin plus fluorouracil with cetuximab at 400 mg/m² initially, then 250 mg/m² weekly)
Study: 18784101
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (cisplatin or carboplatin plus fluorouracil)
Study: 18784623
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg bevacizumab intravitreally in the worst eye
Study: 18786301
Drug: Vagus nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus nerve stimulation (VNS Therapy)
Study: 18794207
Drug: Risperidone (0.5-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5-6 mg/day)
Study: 18794207
Drug: Molindone (10-140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molindone (10-140 mg/day, plus 1 mg/day of benztropine)
Study: 18794456
Drug: Topical estradiol
Normalized name: estradiol Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estradiol 0.01%, 0.1%, 1%, or 2.5%
Study: 18806079
Drug: Positive postnatal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive postnatal thyroid antibody tests
Study: 18812445
Drug: Ambrisentan 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 2.5 mg qd for 4 weeks followed by 5 mg/d for 8 weeks
Study: 18816386
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg IT morphine
Study: 18816386
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg IT morphine
Study: 18816386
Drug: 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg IT morphine
Study: 18816386
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 μg IT morphine)
Study: 18816386
Drug: Control (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (200 μg IT morphine)
Study: 18816386
Drug: Control (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (300 μg IT morphine)
Study: 18823688
Drug: Daily hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hemodialysis (DHD) 6 times/week with the NxStage System One device
Study: 18823688
Drug: Thrice-weekly in-center
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly in-center hemodialysis (HD)
Study: 18825363
Drug: Insulin-resistant (IR)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant (IR) individuals
Study: 18825363
Drug: Insulin-sensitive (IS)
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitive (IS) individuals
Study: 18838471
Drug: High-risk cytogenetics
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk cytogenetics and/or at least two of the following: age >= 75 years, performance status >= 2, white cell count >= 50 x 10(9)/L
Study: 18845370
Drug: eGFR(cysC) of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR(cysC) of 60 to 75 mL/min/1.73 m(2)
Study: 18845370
Drug: eGFR(cysC) less
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR(cysC) less than 60 mL/min/1.73 m(2)
Study: 18852348
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (3 to 9 g per night in split doses over 6 weeks)
Study: 18854394
Drug: Vorinostat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (200 mg twice daily for 2 weeks, followed by 1 week off therapy)
Study: 18854394
Drug: Vorinostat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (200 mg twice daily)
Study: 18854428
Drug: Off treatment
Normalized name: Wart-Off Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off treatment (no r-metHuLeptin)
Study: 18856012
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose continuous veno-venous hemodiafiltration (CVVHDF) at an effluent rate of 40 ml/kg/h
Study: 18856012
Drug: Standard-dose continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose continuous veno-venous hemodiafiltration (CVVHDF) at an effluent rate of 25 ml/kg/h
Study: 18922099
Drug: ATRA (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRA (22.5 mg/m2 twice daily for 2 days)
Study: 18926148
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of statins and beta-blockers at discharge
Study: 18931344
Drug: Obatoclax mesylate
Normalized name: mesylate
DrugBank: Obatoclax (DB12191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obatoclax mesylate (GX15-070) administered at doses ranging from 3.5 to 14 mg/m² as a 1-hour infusion and from 20 to 40 mg/m² as a 3-hour infusion every 3 weeks.
Study: 18931344
Drug: Obatoclax mesylate
Normalized name: mesylate
DrugBank: Obatoclax (DB12191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obatoclax mesylate (GX15-070) administered at maximum tolerated dose (MTD) of 28 mg/m² over 3 hours every 3 weeks.
Study: 18931344
Drug: Obatoclax mesylate
Normalized name: mesylate
DrugBank: Obatoclax (DB12191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obatoclax mesylate (GX15-070) administered to 26 patients.
Study: 18941347
Drug: New therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapies using hormone agonists for treating uremic toxicity
Study: 18942885
Drug: Intermittent, CD4-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent, CD4-guided antiretroviral treatment (ART) - Drug Conservation (DC)
Study: 18945255
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/day) for 48 weeks
Study: 18952896
Drug: Folate-linked radioimaging
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate-linked radioimaging agent
Study: 18955445
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg daily) with temozolomide (TMZ) (75 mg/m² daily) and radiotherapy (RT) (60 Gy)
Study: 18955445
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg daily) with temozolomide (TMZ) (200 mg/m² daily for 5 days every 28 days)
Study: 18955445
Drug: RT/TMZ (European
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT/TMZ (European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada trial 26981/22981)
Study: 18955445
Drug: Nitrosourea-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrosourea-based chemotherapy (historical controls)
Study: 18957506
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 microg twice daily for 15 d
Study: 18971421
Drug: CD45 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD45 monoclonal antibodies (mAbs)
Study: 18971421
Drug: CD45 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD45 monoclonal antibodies (mAbs) followed by EBV-specific CTL infusion
Study: 18974373
Drug: Ipilimumab (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (0.1 to 3.0 mg/kg single infusion)
Study: 18974373
Drug: Ipilimumab (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3.0 mg/kg single infusion)